A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment

Zhao, Xuhong; Ning, Qian; Zhang, Mo; Tang, Shengsong

doi:10.1080/21691401.2019.1657875

Cited by 9 publications

(9 citation statements)

References 112 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an attempt to overcome these, strategies such as smaller antibody fragments (e.g., Fab fragments, single-chain variable fragments and single-domain antibodies, mini-bodies and nanobodies) have been investigated, although they pose unique challenges due to higher clearance rates and significantly shorter half-lives than full-size antibodies [216]. On the other hand, the smaller size antibody fragments are ideal for use in cancer imaging [217,218].…”

Section: Summary and Concluding Remarksmentioning

confidence: 99%

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Arias-Pinilla

Modjtahedi

2021

Cancers

View full text Add to dashboard Cite

Pancreatic cancer remains as one of the most aggressive cancer types. In the absence of reliable biomarkers for its early detection and more effective therapeutic interventions, pancreatic cancer is projected to become the second leading cause of cancer death in the Western world in the next decade. Therefore, it is essential to discover novel therapeutic targets and to develop more effective and pancreatic cancer-specific therapeutic agents. To date, 45 monoclonal antibodies (mAbs) have been approved for the treatment of patients with a wide range of cancers; however, none has yet been approved for pancreatic cancer. In this comprehensive review, we discuss the FDA approved anticancer mAb-based drugs, the results of preclinical studies and clinical trials with mAbs in pancreatic cancer and the factors contributing to the poor response to antibody therapy (e.g. tumour heterogeneity, desmoplastic stroma). MAb technology is an excellent tool for studying the complex biology of pancreatic cancer, to discover novel therapeutic targets and to develop various forms of antibody-based therapeutic agents and companion diagnostic tests for the selection of patients who are more likely to benefit from such therapy. These should result in the approval and routine use of antibody-based agents for the treatment of pancreatic cancer patients in the future.

show abstract

Section: Summary and Concluding Remarksmentioning

confidence: 99%

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Arias-Pinilla

Modjtahedi

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In recent years, antibody fragments have also achieved encouraging successes as theranostic agents contributing to the development of new personalized and more effective medicine. Their tunable pharmacokinetic properties together with the unique ability to detect with high-affinity and specificity biomarkers in vitro and in vivo, making them excellent agents for tumor imaging [184,185].…”

Section: Antibody Fragments As Biotherapeutics and Theranostic Agentsmentioning

confidence: 99%

Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments

Sandomenico

Sivaccumar

Ruvo

2020

IJMS

View full text Add to dashboard Cite

Antibodies and antibody-derived molecules are continuously developed as both therapeutic agents and key reagents for advanced diagnostic investigations. Their application in these fields has indeed greatly expanded the demand of these molecules and the need for their production in high yield and purity. While full-length antibodies require mammalian expression systems due to the occurrence of functionally and structurally important glycosylations, most antibody fragments and antibody-like molecules are non-glycosylated and can be more conveniently prepared in E. coli-based expression platforms. We propose here an updated survey of the most effective and appropriate methods of preparation of antibody fragments that exploit E. coli as an expression background and review the pros and cons of the different platforms available today. Around 250 references accompany and complete the review together with some lists of the most important new antibody-like molecules that are on the market or are being developed as new biotherapeutics or diagnostic agents.

show abstract

“…Herein, antibody fragments become a new strategy in target therapy development [ 16 , 17 ]. According to the smallest form, they are able to resist harsh conditions, pH-stability, and also target the hidden epitope [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach

et al. 2022

View full text Add to dashboard Cite

Background The epidermal growth factor receptor (EGFR) overexpression is found in metastatic colorectal cancer (mCRC). Targeted molecular therapies such as monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) are becoming more precise, targeting specifically for cancer therapeutics. However, there are adverse effects of currently available anti-EGFR drugs, including drug-resistant and side effects. Nanobodies can overcome these limitations. Our previous study has found that cell-penetrable nanobodies targeted at EGFR-tyrosine kinase were significantly reduced EGFR-positive lung cancer cells viability and proliferation. The aim of the present study was to determine the effect of cell-penetrable nanobody (R9VH36) on cell viability and proteomic profile in EGFR-positive human colorectal cancer cell lines. Methods The human colorectal carcinoma cell line (SW480) was treated with R9VH36, compared with gefitinib. Cell viability was monitored using the MTT cell viability assay. The proteomic profiling was analyzed by LC–MS/MS . Results The half-maximal inhibitory concentration (IC50) values determined for R9VH36 and gefitinib against SW480 were 527 ± 0.03 nM and 13.31 ± 0.02 μM, respectively. Moreover, both the gefitinib-treated group and nanobody-treated group had completely different proteome profiles. A total 6626 differentially expressed proteins were identified. PCA analysis revealed different proteome profiling in R9VH36 experiment. There were 8 proteins in R9VH36 that significantly exhibited opposite expression directions when compared to gefitinib. These proteins are involved in DNA-damage checkpoint processes. Conclusion The proteomics explored those 6,626 proteins had different expressions between R9VH36 and gefitinib. There were 8 proteins in R9VH36 exhibited opposite expression direction when comparing to gefitinib. Our findings suggest that R9VH36 has the potential to be an alternative remedy for treating EGFR-positive colon cancer.

show abstract

A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment

Cited by 9 publications

References 112 publications

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments

A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach

Contact Info

Product

Resources

About